Insights

The Problem With BMI

For something that influences doctor visits, insurance categories, fitness goals, and self‑esteem, Body Mass Index carries remarkable authority. It is cited in exam rooms. Printed on medical charts. Built into health apps. Used to classify millions of people as underweight,…

Read MoreThe Problem With BMI
Why 40% of GLP-1 Users Quit for Reasons Beyond Cost

GLP-1 Prices Just Plummeted

This morning, Novo Nordisk delivered a major disruption to the weight-loss and metabolic-health landscape: significantly lower prices for Wegovy and Ozempic. Most versions of the injections dropped from $499 to $349 a month, with new users able to purchase the…

Read MoreGLP-1 Prices Just Plummeted
The Great GLP-1 Reset Has Begun

The Great GLP-1 Reset Has Begun

President Trump’s new Medicare deal with Eli Lilly & Company and Novo Nordisk has reshaped the economics of weight loss. High-demand GLP-1 drugs such as Wegovy and Zepbound, once a $1,000-a-month treatment for a select few, will soon be available for about $245 under…

Read MoreThe Great GLP-1 Reset Has Begun